PMID- 20945821
OWN - NLM
STAT- MEDLINE
DCOM- 20101207
LR  - 20211020
IS  - 1844-122X (Print)
IS  - 1844-3117 (Electronic)
IS  - 1844-122X (Linking)
VI  - 3
IP  - 3
DP  - 2010 Jul-Sep
TI  - Cerebrolysin adjuvant treatment in Broca's aphasics following first acute 
      ischemic stroke of the left middle cerebral artery.
PG  - 297-307
AB  - BACKGROUND: The aim of our study was to assess the efficacy of Cerebrolysin 
      administration in Broca's aphasics with acute ischemic stroke. METHODS: We 
      registered 2212 consecutive Broca's aphasics following an acute ischemic stroke 
      admitted in four departments of neurology in Romania, between September 2005 and 
      September 2009. Language was evaluated with the Romanian version of the Western 
      Aphasia Battery (WAB). The following inclusion criteria were used for this study: 
      age 20-75 years, admission in the hospital within 12 hours from the onset of the 
      symptoms, diagnosis of first acute left middle cerebral artery (MCA) ischemic 
      stroke, presence of large artery disease (LAD) stroke, a NIHSS score of 5-22 
      points, and a therapeutic time window within 72 h. Fifty two patients were 
      treated with Cerebrolysin (Cerebrolysin group) as an adjunctive treatment. A 
      placebo group, which received saline infusions (n=104 patients) were matched to 
      the NIHSS and WAB scores, gender and age of the Cerebrolysin group at baseline. 
      We assessed spontaneous speech (SS), comprehension (C), repetition (R), naming 
      (N), and Aphasia Quotient (AQ) scores of the two groups in an open label design, 
      over 90 days, the mRS scores and mortality. RESULTS: The Cerebrolysin and the 
      placebo groups had similar age (66 +/- 8 versus 65 +/- 8 years) and sex ratio 
      (14/38 versus 30/74). The mean AQ scores and the mean subscores for 3 subtests of 
      WAB (SS, R, N) were similar at baseline and improved in the Cerebrolysin group 
      significantly (p < 0.05) over placebo group at all study time points. The mRS 
      score at 90 days was also lower in the Cerebrolysin group than in the placebo 
      group. Cerebrolysin and placebo were both tolerated and safe, and no difference 
      in the mortality rate was seen (3.8% in each group). CONCLUSION: Cerebrolysin is 
      effective for the treatment of Broca's aphasics with a first acute ischemic 
      stroke of the left MCA territory.
FAU - Jianu, Dragos Catalin
AU  - Jianu DC
AD  - Department of Neurology, [corrected] Victor Babes University of Medicine and 
      Pharmacy, Clinical Emergency County Hospital, [corrected] Timisoara, Romania. 
      dcjianu@yahoo.com
FAU - Muresanu, Dafin Fior
AU  - Muresanu DF
FAU - Bajenaru, Ovidiu
AU  - Bajenaru O
FAU - Popescu, Bogdan Ovidiu
AU  - Popescu BO
FAU - Deme, Sanda Maria
AU  - Deme SM
FAU - Moessler, Herbert
AU  - Moessler H
FAU - Meinzingen, Sibilla Zimmermann
AU  - Meinzingen SZ
FAU - Petrica, Ligia
AU  - Petrica L
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Romania
TA  - J Med Life
JT  - Journal of medicine and life
JID - 101477617
RN  - 0 (Amino Acids)
RN  - 0 (Neuroprotective Agents)
RN  - 37KZM6S21G (cerebrolysin)
SB  - IM
EIN - J Med Life. 2011 Jan-Mar;4(1):7 p following 123. Petria, Ligia [corrected to 
      Petrica, Ligia]
MH  - Adult
MH  - Aged
MH  - Amino Acids/*therapeutic use
MH  - Aphasia, Broca/*drug therapy/*etiology/psychology
MH  - Chemotherapy, Adjuvant
MH  - Female
MH  - Humans
MH  - Infarction, Middle Cerebral Artery/*complications/diagnosis
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/*therapeutic use
MH  - Romania
MH  - Young Adult
PMC - PMC3019000
EDAT- 2010/10/16 06:00
MHDA- 2010/12/14 06:00
PMCR- 2010/10/15
CRDT- 2010/10/16 06:00
PHST- 2010/10/16 06:00 [entrez]
PHST- 2010/10/16 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
PHST- 2010/10/15 00:00 [pmc-release]
AID - JMedLife-03-297 [pii]
PST - ppublish
SO  - J Med Life. 2010 Jul-Sep;3(3):297-307.